India's Union Health Ministry has banned the manufacture, sale, and distribution of all oral formulations of the painkiller nimesulide above 100 mg for human use, citing health risks and the availability of safer alternatives. This decision follows a report by the Indian Council of Medical Research (ICMR) highlighting concerns over liver damage and other adverse effects, particularly in the elderly and those under 18. The ban, effective immediately, aligns with previous restrictions on pediatric use and aims to enhance public health safety.